GBI Research, the leading business intelligence provider, has released its latest research: Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - Increased Uptake of High Priced Drugs to Offset the Impact of Generics, which provides in-depth analysis of the Colorectal Cancer (CRC) therapeutics market in the eight major geographies of the US, Canada, the UK, France, Germany, Spain, Italy and Japan. The report provides an estimation of the market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth pipeline analysis, and deal analysis.
The CRC therapeutics market in the eight major markets is expected to grow at a Compound Annual Growth Rate (CAGR) of 1.8% to $9.4 billion by 2020. The US had the largest market share in 2013, equivalent to a global share of 44.1%, followed by Japan and Germany with 14.7% and 11.9% respectively. Spain had the lowest market share of the leading eight at 4.1%. All markets covered in the report are expected to witness a slower growth rate than Japan, which will grow at a CAGR of 5%. However, this moderate growth will be stymied by the expected uptake of lower-priced biosimilar versions of bevacizumab and cetuximab due to the expiration of the patents of Avastin and Erbitux in the latter half of the forecast period. Also expected is the launch of generic versions of capecitabine, which will also affect the market. However, this will be offset by the launch of premium-priced emerging therapies. Stivarga is expected to be one of the biggest drivers of growth in the CRC market, primarily due to its expected line extension in the first-line metastatic setting as a maintenance treatment for patients with resected liver metastases. The launch of Lonsurf (TAS-102), approved in Japan in 2014, in the third- and fourth-line settings will further increase the pharmacological treatment rates in these lines, which will give patients a more tolerable alternative to Stivarga. The moderate uptake of other late-stage pipeline products, panitumumab and Xilonix, following their expected approval, is expected to drive additional growth within this market.
The CRC pipeline is highly robust, with potential drug candidates across various Phases of clinical development. With nearly 400 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of CRC in advanced stages, either as first-line or second-line therapies. The current investigational pipeline candidates include new combination therapies and targeted therapies, as well as promising immunotherapies and chemotherapy drug candidates. As well as these active progressing pipeline molecules, the pipeline also includes nearly 180 molecules that are either inactive or discontinued.
Scope
The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the eight major markets: the US, the UK, France, Germany, Spain, Italy, Japan and Canada. It includes:
Reasons To Buy
The report will enhance your decision-making capability by allowing you to:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Colorectal Cancer
2.2 Symptoms
2.3 Epidemiology
2.4 Pathophysiology
2.4.1 Histology
2.4.2 Genetic Basis
2.4.3 Etiology of Colorectal Cancer
2.5 Diagnosis
2.5.1 Digital Rectal Examination
2.5.2 Fecal Occult Blood Test
2.5.3 Flexible Sigmoidoscopy
2.5.4 Colonoscopy
2.5.5 Virtual Colonoscopy
2.5.6 Double Contrast Barium Enema
2.6 Prognosis and Disease Staging
2.7 Treatment Options
2.7.1 Surgery and Radiation Therapy
2.7.2 Chemotherapy
2.7.3 Targeted Therapies
2.7.4 Resistance to Pharmacological Therapies
2.7.5 Treatment Guidelines
2.8 GBI Research Report Guidance
3 Marketed Products
3.1 Key Marketed Products
3.1.1 Immunotherapies
3.1.2 Targeted Therapies
3.1.3 Hyperthermic Intraperitoneal Chemotherapy
3.2 Heat Map for Marketed Products
4 Pipeline Analysis
4.1 Overall Pipeline
4.2 Pipeline Analysis by Molecule Type
4.3 Pipeline Analysis by Mechanism of Action
4.4 Clinical Trials
4.5 Failure Rate
4.6 Clinical Trial Size
4.7 Duration
4.8 Promising Drug Candidates in Pipeline
4.8.1 Lonsurf (TAS-102 (tipiracil + trifluridine)) – Taiho Pharmaceutical
4.8.2 Cyramza – ramucirumab – Eli Lilly and Company
4.8.3 TS-1/Teysuno (tegafur + gimeracil + oteracil) – Taiho Pharmaceutical
4.8.4 CPP-1X (eflornithine hydrochloride) + sulindac – Cancer Prevention Pharmaceuticals
4.8.5 MelCancerVac – DanDrit Biotech
4.8.6 Xilonix – XBiotech
4.8.7 Nintedanib – Boehringer Ingelheim
5 Market Forecast to 2020
5.1 Global Market
5.1.1 Treatment Use Patterns
5.1.2 Market Size
5.2 North America
5.2.1 Treatment Use Patterns
5.2.2 Annual Cost of Therapy
5.2.3 Market Size
5.3 Top Five European Markets
5.3.1 Treatment Use Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 Japan
5.4.1 Treatment Use Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Drivers and Barriers for the Colorectal Cancer Therapeutics in Major Developed Markets to 2020
5.5.1 Drivers
5.5.2 Barriers
6 Deals and Strategic Consolidations
6.1 Licensing Agreements
6.1.1 Major Licensing Deals
6.2 Co-development Agreements
6.2.1 Major Co-development Agreements
7 Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND/CTA-Filed
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.2 Market Forecasts to 2020
7.2.1 Global
7.2.2 US
7.2.3 Canada
7.2.4 UK
7.2.5 France
7.2.6 Germany
7.2.7 Italy
7.2.8 Spain
7.2.9 Japan
7.3 Market Definitions
7.4 Abbreviations
7.5 References
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer
List of Tables
Table 1 Colorectal Cancer Therapeutics, Global, TNM Staging, 2013
Table 2 Surgical Options for Colorectal Cancer
Table 3 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2014
Table 4 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2014
Table 5 Colorectal Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed), 2014
Table 6 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2014
Table 7 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2014
Table 8 Colorectal Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2014
Table 9: Colorectal Cancer Therapeutics, Global, Forecast Data, 2013–2020
Table 10: Colorectal Cancer Therapeutics, US, Forecast Data, 2013–2020
Table 11: Colorectal Cancer Therapeutics, Canada, Forecast Data, 2013–2020
Table 12: Colorectal Cancer Therapeutics, UK, Forecast Data, 2013–2020
Table 13: Colorectal Cancer Therapeutics, France, Forecast Data, 2013–2020
Table 14: Colorectal Cancer Therapeutics, Germany, Forecast Data, 2013–2020
Table 15: Colorectal Cancer Therapeutics, Italy, Forecast Data, 2013–2020
Table 16: Colorectal Cancer Therapeutics, Spain, Forecast Data, 2013–2020
Table 17: Colorectal Cancer Therapeutics, Japan, Forecast Data, 2013–2020
List of Figures
Figure 1: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology Treatment Guidelines (Colorectal Cancer at Stage I to III)
Figure 2: Colorectal Cancer Therapeutics, Global, European Society for Medical Oncology Treatment Guidelines (Colorectal Cancer at Stage IV)
Figure 3: Colorectal Cancer Therapeutics, Global, Heat Map (Marketed Products)
Figure 4: Colorectal Cancer Therapeutics, Global, Pipeline by Stage of Development and Program Type, 2014
Figure 5: Colorectal Cancer Therapeutics, Global, Pipeline by Molecule Type and Stage of Development, 2014
Figure 6: Colorectal Cancer Therapeutics, Global, Pipeline by Mechanism of Action and Stage of Development, 2014
Figure 7: Colorectal Cancer Therapeutics, Global, Clinical Trial Failure Rate (%), 2014
Figure 8: Colorectal Cancer Therapeutics, Global, Clinical Trial Size, 2014
Figure 9: Colorectal Cancer Therapeutics, Global, Clinical Trial Duration (months), 2014
Figure 10: Colorectal Cancer Therapeutics, Global, Treatment Use Patterns (‘000) and Market Size ($bn), 2013–2020
Figure 11: Colorectal Cancer Therapeutics, US and Canada, Treatment Use Patterns (‘000), 2013–2020
Figure 12: Colorectal Cancer Therapeutics, US and Canada, Annual Cost of Therapy ($), 2013–2020
Figure 13: Colorectal Cancer Therapeutics, US and Canada, Market Size ($m), 2013–2020
Figure 14: Colorectal Cancer Therapeutics, Top Five European Markets, Treatment Use Patterns (‘000), 2013–2020
Figure 15: Colorectal Cancer Therapeutics, Top Five European Markets, Annual Cost of Therapy ($), 2013–2020
Figure 16: Colorectal Cancer Therapeutics, Top Five European Markets, Market Size ($m), 2013–2020
Figure 17: Colorectal Cancer Therapeutics, Japan, Treatment Use Pattern, 2013–2020
Figure 18: Colorectal Cancer Therapeutics, Japan, Annual Cost of Therapy, 2013–2020
Figure 19: Colorectal Cancer Therapeutics, Japan, Market Size ($m), 2013–2020
Figure 20: Colorectal Cancer Therapeutics, Global, Licensing Deals by Geography, 2006–2014
Figure 21: Colorectal Cancer Therapeutics, Global, Licensing Deals by Phase, Value, Mechanism of Action, 2006–2014
Figure 22: Colorectal Cancer Market, Global, Co-development Deals by Geography and by Value, 2006–2014
Figure 23: GBI Research Market Forecasting Model.
Contact us at the Consulting WP office nearest to you or submit a business inquiry online.
Subscribe to Our Newsletter
Published On : December 2019
$ 3600
Published On : November 2019
$ 3600
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
Published On : October 2019
$ 2950
